Cargando…

Piracetam and vinpocetine ameliorate rotenone-induced Parkinsonism in rats

OBJECTIVE: To evaluate the neuroprotective effect of the nootropic drugs, piracetam (PIR) and vinpocetine (VIN), in rotenone-induced Parkinsonism in rats. MATERIALS AND METHODS: Sixty male rats were divided into 6 groups of 10 rats each. The groups were administered vehicle, control (rotenone, 1.5 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Zaitone, Sawsan A., Abo-Elmatty, Dina M., Elshazly, Shimaa M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3523508/
https://www.ncbi.nlm.nih.gov/pubmed/23248410
http://dx.doi.org/10.4103/0253-7613.103300
_version_ 1782253217541783552
author Zaitone, Sawsan A.
Abo-Elmatty, Dina M.
Elshazly, Shimaa M.
author_facet Zaitone, Sawsan A.
Abo-Elmatty, Dina M.
Elshazly, Shimaa M.
author_sort Zaitone, Sawsan A.
collection PubMed
description OBJECTIVE: To evaluate the neuroprotective effect of the nootropic drugs, piracetam (PIR) and vinpocetine (VIN), in rotenone-induced Parkinsonism in rats. MATERIALS AND METHODS: Sixty male rats were divided into 6 groups of 10 rats each. The groups were administered vehicle, control (rotenone, 1.5 mg/kg/48 h/6 doses, s.c.), PIR (100 and 200 mg/kg/day, p.o.) and VIN (3 and 6 mg/kg/day, p.o.). The motor performance of the rats was evaluated by the open field and pole test. Striatal dopamine level, malondialdehyde (MDA), reduced glutathione (GSH) and tumor necrosis factor-α (TNF-α) were assayed. Histopathological study of the substantia nigra was also done. RESULTS: Results showed that rotenone-treated rats exhibited bradykinesia and motor impairment in the open-field test. In addition, GSH level was decreased whereas MDA and TNF-α increased in striata of rotenone-treated rats as compared to vehicle-treated rats. Marked degeneration of the substantia nigra pars compacta (SNpc) neurons and depletion of striatal dopamine was also observed in the rotenone-treated rats. Treatment with PIR or VIN significantly reversed the locomotor deficits and increased striatal dopamine level. Treatment with VIN significantly (P < 0.05) reduced the striatal level of MDA and GSH in comparison to rotenone group whereas TNF-α production was found to be significantly decreased in PIR group (P < 0.05). CONCLUSION: VIN and PIR exhibit neuroprotective activity in rotenone-induced Parkinsonism. Hence, these nootropic agents may be considered as possible candidates in the treatment of Parkinson's disease.
format Online
Article
Text
id pubmed-3523508
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-35235082012-12-17 Piracetam and vinpocetine ameliorate rotenone-induced Parkinsonism in rats Zaitone, Sawsan A. Abo-Elmatty, Dina M. Elshazly, Shimaa M. Indian J Pharmacol Research Article OBJECTIVE: To evaluate the neuroprotective effect of the nootropic drugs, piracetam (PIR) and vinpocetine (VIN), in rotenone-induced Parkinsonism in rats. MATERIALS AND METHODS: Sixty male rats were divided into 6 groups of 10 rats each. The groups were administered vehicle, control (rotenone, 1.5 mg/kg/48 h/6 doses, s.c.), PIR (100 and 200 mg/kg/day, p.o.) and VIN (3 and 6 mg/kg/day, p.o.). The motor performance of the rats was evaluated by the open field and pole test. Striatal dopamine level, malondialdehyde (MDA), reduced glutathione (GSH) and tumor necrosis factor-α (TNF-α) were assayed. Histopathological study of the substantia nigra was also done. RESULTS: Results showed that rotenone-treated rats exhibited bradykinesia and motor impairment in the open-field test. In addition, GSH level was decreased whereas MDA and TNF-α increased in striata of rotenone-treated rats as compared to vehicle-treated rats. Marked degeneration of the substantia nigra pars compacta (SNpc) neurons and depletion of striatal dopamine was also observed in the rotenone-treated rats. Treatment with PIR or VIN significantly reversed the locomotor deficits and increased striatal dopamine level. Treatment with VIN significantly (P < 0.05) reduced the striatal level of MDA and GSH in comparison to rotenone group whereas TNF-α production was found to be significantly decreased in PIR group (P < 0.05). CONCLUSION: VIN and PIR exhibit neuroprotective activity in rotenone-induced Parkinsonism. Hence, these nootropic agents may be considered as possible candidates in the treatment of Parkinson's disease. Medknow Publications & Media Pvt Ltd 2012 /pmc/articles/PMC3523508/ /pubmed/23248410 http://dx.doi.org/10.4103/0253-7613.103300 Text en Copyright: © Indian Journal of Pharmacology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Zaitone, Sawsan A.
Abo-Elmatty, Dina M.
Elshazly, Shimaa M.
Piracetam and vinpocetine ameliorate rotenone-induced Parkinsonism in rats
title Piracetam and vinpocetine ameliorate rotenone-induced Parkinsonism in rats
title_full Piracetam and vinpocetine ameliorate rotenone-induced Parkinsonism in rats
title_fullStr Piracetam and vinpocetine ameliorate rotenone-induced Parkinsonism in rats
title_full_unstemmed Piracetam and vinpocetine ameliorate rotenone-induced Parkinsonism in rats
title_short Piracetam and vinpocetine ameliorate rotenone-induced Parkinsonism in rats
title_sort piracetam and vinpocetine ameliorate rotenone-induced parkinsonism in rats
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3523508/
https://www.ncbi.nlm.nih.gov/pubmed/23248410
http://dx.doi.org/10.4103/0253-7613.103300
work_keys_str_mv AT zaitonesawsana piracetamandvinpocetineamelioraterotenoneinducedparkinsonisminrats
AT aboelmattydinam piracetamandvinpocetineamelioraterotenoneinducedparkinsonisminrats
AT elshazlyshimaam piracetamandvinpocetineamelioraterotenoneinducedparkinsonisminrats